相关实验视频
Updated: Jun 22, 2025

05:50
Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
1.1K
改变疾病的骨关节炎药物的前景
1Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar; Rheumatology Department, Royal North Shore Hospital, Institute of Bone and Joint Research, Kolling Institute, The University of Sydney, Sydney, Australia.
Rheumatic diseases clinics of North America
|June 28, 2024
概括
骨关节炎的治疗方法缺乏,但针对炎症,骨或软骨的新型疾病修饰药物 (DMOAD) 正在开发中. 有研究机会来改进这些有前途的关节炎治疗的临床试验设计.
科学领域:
- 风湿病学和药物开发
- 生物医学研究和临床试验
背景情况:
- 骨关节炎 (OA) 是一个重大的全球健康挑战,在2020年影响了近23%的人口.
- 目前的骨关节炎治疗主要是治疗症状,对疾病修饰性骨关节炎药物 (DMOADs) 的需求至关重要.
研究的目的:
- 在2/3期临床试验中审查活跃的DMOAD候选者.
- 根据关键的骨关节炎病原体机制分析这些候选者:由炎症驱动的,由骨驱动的和由软骨驱动的内型.
- 确定挑战和研究机会,以推进OA药物开发.
主要方法:
- 在晚期临床开发中对DMOAD候选者的文献综述.
- 根据OA内型对候选药物的分类.
- 使用PICO方法 (人口,干预,比较,结果) 制定研究问题框架.
主要成果:
- 针对不同OA内型的几个DMOAD候选药物正在进行临床试验.
- 该审查强调了OA病变的复杂性和需要有针对性的治疗策略.
- 该PICO方法提供了一个结构化的方法来设计未来的OA临床试验.
结论:
- 对DMOADs的积极研究为改善骨关节炎管理提供了希望.
- 了解OA内型对于开发有效的向疗法至关重要.
- 通过像PICO这样的结构化方法优化临床试验设计对于成功的药物开发至关重要.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
271
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
271
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130

